Stem Cell Firm Regeneus Raising Targets $10 Million

Published: Aug 19, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

REGENEUS executive chairman John Martin blanches at suggestions the regenerative medicine minnow is a poor man's alternative to stem-cell play Mesoblast, which commands a $1.9 billion market valuation. "We are not a poor man's anyone -- we have our own story," Mr Martin said, adding "There's no doubt Mesoblast has done a good job priming the Australian market about stem-cell therapies." In the first non-device biotech listing in more than two years, Regeneus principals are seeking to raise $10 million in an IPO, valuing the Sydney-based human and veterinary therapy outfit at $45m.

Help employers find you! Check out all the jobs and post your resume.

Back to news